Dov A. Goldstein MD

Dov A. Goldstein MD is a declared insider at 8 companies (board member); the most frequent names are Cempra, Inc., Esperion Therapeutics, Inc. and BioAge Labs, Inc. Between 7 February 2012 and 23 April 2026, the trades on record add up to 55 filings.

The open-market side counts 8 purchases for €20.5M alongside 16 sales for €58.6M. The amount is not disclosed for 1 filing. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 3 share grants and 18 option exercises. So far in 2026, the count stands at no purchases and 4 sales.

In size, the median ticket on the buying side is €2.6M. On 2 out of 4 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster.

Most recently, on 24 April 2026, the filings show an option exercise worth €13k in BioAge Labs, Inc. The clock since the last published purchase (4 January 2023) now reads 1,389 days. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.